Analysts Offer Insights on Healthcare Companies: Cooper Co (COO), Cencora (COR) and Caribou Biosciences (CRBU)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cooper Co (COO – Research Report), Cencora (COR – Research Report) and Caribou Biosciences (CRBU – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cooper Co (COO)
In a report released yesterday, Travis Steed from Bank of America Securities reiterated a Buy rating on Cooper Co, with a price target of $96.00. The company’s shares closed last Thursday at $80.20, close to its 52-week low of $77.05.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cooper Co with a $90.25 average price target, an 11.7% upside from current levels. In a report issued on February 23, Needham also maintained a Buy rating on the stock with a $99.00 price target.
See today’s best-performing stocks on TipRanks >>
Cencora (COR)
Bank of America Securities analyst Allen Lutz reiterated a Hold rating on Cencora today and set a price target of $380.00. The company’s shares closed last Thursday at $359.28.
According to TipRanks.com, Lutz is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cencora with a $414.22 average price target, a 13.6% upside from current levels. In a report issued on February 20, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $389.00 price target.
Caribou Biosciences (CRBU)
In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Caribou Biosciences, with a price target of $6.00. The company’s shares closed last Thursday at $1.71.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Caribou Biosciences with a $9.00 average price target, representing a 402.8% upside. In a report issued on February 20, Citi also maintained a Buy rating on the stock with a $8.00 price target.
